PRE-HOSPITAL TREATMENT OF STATUS EPILEPTICUS

癫痫持续状态的院前治疗

基本信息

项目摘要

Status epilepticus (SE) occurs in 45,000 to 65,000 persons annually in the United States and is a medical emergency that requires prompt, effective intervention. Despite the development of effective anticonvulsant therapies, and the recognition that prolonged SE is associated with poor neurological outcome, there is often a significant delay between the onset of SE and successful termination of seizures with conventional treatment. This is due both to the time required for transport of patients to an emergency care facility and, in a significant number of patients, a lack of response to initial anticonvulsant treatment. In 1990, the San Francisco Emergency Medical Services (EMS) system developed a protocol that allowed paramedics to administer intravenous diazepam for the treatment of SE in the field. A preliminary analysis of this protocol suggests that patients who received pre-hospital diazepam therapy had fewer seizures in the emergency department, SE of shorter duration, and were intubated less often than patients in whom conventional anticonvulsant therapy was initiated after hospital arrival. These data indicate that pre-hospital treatment of SE may simplify subsequent management and have a beneficial impact on the clinical course and outcome of patients. Nonetheless, the potential benefits and complications of this treatment strategy have not been assessed in a rigorous manner. This is of particular concern because the respiratory complications of intravenous diazepam may be severe, and reports from EMS systems elsewhere in the U.S. suggest that pre-hospital benzodiazepine therapy of SE is gaining popularity despite the lack of a well designed clinical trial to assess its value. This grant proposal describes a multicenter, prospective, randomized, double-blind study designed to compare the safety and efficacy of intravenous diazepam or lorazepam versus placebo when administered in the field by paramedics to adult patients in SE. The study takes advantage of the highly-centralized San Francisco EMS system which is based at San Francisco General Hospital (SFGH). Paramedics will verify the diagnosis of SEE, administer study drugs, and assess patients during transport while having continual radio contact with an attending physician and Medical Intensive Care Nurse at SFGH. The assessment of patients will include observations of clinical seizure activity, level of consciousness, vital signs, cardiac rhythms, and oxygenation via pulse oximetry. Paramedics will also hook-up an ambulatory EEG recording unit to each study patient at the time of initial contact, and continuous recordings will be maintained throughout the transit and emergency department phase of the study. These recordings will be subsequently interpreted and used to determine the validity of the SE diagnosis by the EMS system. Patients will receive standardized anticonvulsant treatment at the destination hospital, and will be monitored for seizure recurrence, cardiovascular and respiratory complications, need for subsequent intensive care, and neurological condition at discharge. Univariate and multivariate statistical comparisons will be used to determine whether pre-hospital therapy has a significant impact on the management and outcome of patients during transport and subsequent hospitalization.
癫痫持续状态(SE)每年在美国发生45,000至65,000人

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DANIEL H LOWENSTEIN其他文献

DANIEL H LOWENSTEIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DANIEL H LOWENSTEIN', 18)}}的其他基金

Epi25 Clinical Phenotyping R03
Epi25 临床表型 R03
  • 批准号:
    9753389
  • 财政年份:
    2018
  • 资助金额:
    $ 39.84万
  • 项目类别:
The Epilepsy Phenome/ Genome Project (EPGP)
癫痫表型组/基因组计划 (EPGP)
  • 批准号:
    8603145
  • 财政年份:
    2013
  • 资助金额:
    $ 39.84万
  • 项目类别:
2 of 7 EPI4K - Phenotyping Clinical Informatics Core
2 of 7 EPI4K - 表型临床信息学核心
  • 批准号:
    8338460
  • 财政年份:
    2011
  • 资助金额:
    $ 39.84万
  • 项目类别:
2 of 7 EPI4K - Phenotyping Clinical Informatics Core
2 of 7 EPI4K - 表型临床信息学核心
  • 批准号:
    8533048
  • 财政年份:
    2011
  • 资助金额:
    $ 39.84万
  • 项目类别:
2 of 7 EPI4K - Phenotyping Clinical Informatics Core
2 of 7 EPI4K - 表型临床信息学核心
  • 批准号:
    8240658
  • 财政年份:
    2011
  • 资助金额:
    $ 39.84万
  • 项目类别:
The Epilepsy Phenome/ Genome Project (EPGP)
癫痫表型组/基因组计划 (EPGP)
  • 批准号:
    7846727
  • 财政年份:
    2007
  • 资助金额:
    $ 39.84万
  • 项目类别:
The Epilepsy Phenome/ Genome Project (EPGP)
癫痫表型组/基因组计划 (EPGP)
  • 批准号:
    7409158
  • 财政年份:
    2007
  • 资助金额:
    $ 39.84万
  • 项目类别:
The Epilepsy Phenome/ Genome Project (EPGP)
癫痫表型组/基因组计划 (EPGP)
  • 批准号:
    7614162
  • 财政年份:
    2007
  • 资助金额:
    $ 39.84万
  • 项目类别:
The Epilepsy Phenome/ Genome Project (EPGP)
癫痫表型组/基因组计划 (EPGP)
  • 批准号:
    7912378
  • 财政年份:
    2007
  • 资助金额:
    $ 39.84万
  • 项目类别:
The Epilepsy Phenome/ Genome Project (EPGP)
癫痫表型组/基因组计划 (EPGP)
  • 批准号:
    7197009
  • 财政年份:
    2007
  • 资助金额:
    $ 39.84万
  • 项目类别:

相似海外基金

From lymphatics to evaluating resolution therapeutics in clinical trials
从淋巴管到评估临床试验中的解决疗法
  • 批准号:
    MR/Y013050/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.84万
  • 项目类别:
    Fellowship
RareKids-CAN: Pediatric Rare Disease Clinical Trials and Treatment Network
RareKids-CAN:儿科罕见病临床试验和治疗网络
  • 批准号:
    495575
  • 财政年份:
    2023
  • 资助金额:
    $ 39.84万
  • 项目类别:
    Operating Grants
Core B: Clinical Trials Core
核心 B:临床试验核心
  • 批准号:
    10554476
  • 财政年份:
    2023
  • 资助金额:
    $ 39.84万
  • 项目类别:
Unbiased estimation in hierarchical models for Clinical trials
临床试验分层模型中的无偏估计
  • 批准号:
    2884930
  • 财政年份:
    2023
  • 资助金额:
    $ 39.84万
  • 项目类别:
    Studentship
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 39.84万
  • 项目类别:
NIDA Clinical Trials Network: New York Node
NIDA 临床试验网络:纽约节点
  • 批准号:
    10855627
  • 财政年份:
    2023
  • 资助金额:
    $ 39.84万
  • 项目类别:
CCTN-CONTRACEPTIVE DEVELOPMENT PROGRAM-NICHD CONTRACEPTIVE CLINICAL TRIALS NETWORK-FEMALE SITES-CORE FUNCTION ACTIVITIES
CCTN-避孕发展计划-NICHD避孕临床试验网络-女性站点-核心功能活动
  • 批准号:
    10895949
  • 财政年份:
    2023
  • 资助金额:
    $ 39.84万
  • 项目类别:
CONTRACEPTIVE CLINICAL TRIALS NETWORK, CCTN - FEMALE SITES 'CORE FUNCTION ACTIVITIES
避孕临床试验网络,CCTN - 女性站点的核心功能活动
  • 批准号:
    10891325
  • 财政年份:
    2023
  • 资助金额:
    $ 39.84万
  • 项目类别:
ISimcha Technology Platform for Recruiting a Diverse Population of Older Adults into Clinical Trials
ISimcha 技术平台,用于招募不同的老年人群进行临床试验
  • 批准号:
    10761602
  • 财政年份:
    2023
  • 资助金额:
    $ 39.84万
  • 项目类别:
Implementing HIV/Cervical Cancer Prevention CASCADE Clinical Trials in Zimbabwe (ZIM-CASCADE)
在津巴布韦实施艾滋病毒/宫颈癌预防 CASCADE 临床试验 (ZIM-CASCADE)
  • 批准号:
    10758129
  • 财政年份:
    2023
  • 资助金额:
    $ 39.84万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了